最新进展与新出现的选择：氨磷汀作为一种广谱细胞保护剂的作用 - Suppr

Suppr

超能文献

Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.

作者信息

Capizzi R L

机构信息

Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.

出版信息

Semin Oncol. 1999 Apr;26(2 Suppl 7):1-2.

PMID:10348254

Abstract

摘要

相似文献

Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.

Semin Oncol. 1999 Apr;26(2 Suppl 7):1-2.

Amifostine and combined-modality therapeutic approaches.

Semin Oncol. 1999 Apr;26(2 Suppl 7):95-101.

Future development of amifostine as a radioprotectant.

Semin Oncol. 1999 Apr;26(2 Suppl 7):129-34.

[Development of cancer chemotherapy. Cytoprotective agents].

Clin Ter. 2001 Mar-Apr;152(2):135-43.

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.

Semin Oncol. 1999 Apr;26(2 Suppl 7):3-21.

Randomized trials of amifostine and radiotherapy: effect on survival?

Semin Oncol. 2004 Dec;31(6 Suppl 18):62-6. doi: 10.1053/j.seminoncol.2004.12.015.

Future directions in gynecologic cancer.

Semin Oncol. 1999 Apr;26(2 Suppl 7):125-8.

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.

Semin Oncol. 1999 Apr;26(2 Suppl 7):72-81.

Potential for use of amifostine in cervical cancer.

Semin Oncol. 2002 Dec;29(6 Suppl 19):34-7. doi: 10.1053/sonc.2002.37366.

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.

J Clin Oncol. 2002 Jun 15;20(12):2895-903. doi: 10.1200/JCO.2002.04.178.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.

作者信息

Capizzi R L

机构信息

Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.

出版信息

Semin Oncol. 1999 Apr;26(2 Suppl 7):1-2.

PMID:10348254

Abstract

摘要

相似文献

Recent developments and emerging options: the role of amifostine as a broad-spectrum cytoprotective agent.

Semin Oncol. 1999 Apr;26(2 Suppl 7):1-2.

Amifostine and combined-modality therapeutic approaches.

Semin Oncol. 1999 Apr;26(2 Suppl 7):95-101.

Future development of amifostine as a radioprotectant.

Semin Oncol. 1999 Apr;26(2 Suppl 7):129-34.

[Development of cancer chemotherapy. Cytoprotective agents].

Clin Ter. 2001 Mar-Apr;152(2):135-43.

The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.

Semin Oncol. 1999 Apr;26(2 Suppl 7):3-21.

Randomized trials of amifostine and radiotherapy: effect on survival?

Semin Oncol. 2004 Dec;31(6 Suppl 18):62-6. doi: 10.1053/j.seminoncol.2004.12.015.

Future directions in gynecologic cancer.

Semin Oncol. 1999 Apr;26(2 Suppl 7):125-8.

Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.

Semin Oncol. 1999 Apr;26(2 Suppl 7):72-81.

Potential for use of amifostine in cervical cancer.

Semin Oncol. 2002 Dec;29(6 Suppl 19):34-7. doi: 10.1053/sonc.2002.37366.

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.

J Clin Oncol. 2002 Jun 15;20(12):2895-903. doi: 10.1200/JCO.2002.04.178.